

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS   | NON-PREFERRED AGENTS   | PA CRITERIA   |
|--|--|--|---|
| <b>ACE INHIBITORS</b><br><br><i>Effective 10/2/06</i>                                    | <b>ACE INHIBITORS</b>  |  | Four of the preferred agents must be tried for at least 30 days each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.  |
|  | ACEON (perindopril)<br>ALTACE (ramipril)<br>benazepril<br>captopril<br>enalapril<br>lisinopril<br>MAVIK (trandolapril) | ACCUPRIL (quinapril)<br>CAPOTEN (captopril)<br>fosinopril<br>LOTENSIN (benazepril)<br>moexepiril<br>MONOPRIL (fosinopril)<br>PRINIVIL (lisinopril)<br>quinapril<br><b>trandolapril</b><br>UNIVASC (moexepiril)<br>VASOTEC (enalapril)<br>ZESTRIL (lisinopril)                              |   |
| <b>ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS</b><br><br><i>Effective 4/2/07</i> | <b>ACE INHIBITOR/DIURETIC COMBINATIONS</b>   |  | Each of the preferred agents must be tried for at least two weeks each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br>Patients starting therapy in this class must show a documented allergy to the preferred agents before a non-preferred agent will be authorized. |
|  | benazepril/HCTZ<br>captopril/HCTZ<br>enalapril/HCTZ<br>lisinopril/HCTZ   | ACCURETIC (quinapril/HCTZ)<br>CAPOZIDE (captopril/HCTZ)<br>fosinopril/HCTZ<br>LOTENSIN HCT (benazepril/HCTZ)<br>MONOPRIL HCT (fosinopril/HCTZ)<br>PRINZIDE (lisinopril/HCTZ)<br>quinapril/HCTZ<br>UNIRETIC (moexepiril/HCTZ)<br>VASERETIC (enalapril/HCTZ)<br>ZESTORETIC (lisinopril/HCTZ) |   |
|  | LOTREL (benazepril/amlodipine)<br>TARKA (trandolapril/verapamil)   | <b>amlodipine/benazepril</b><br>LEXXEL (enalapril/felodipine)  |   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS                                     | PREFERRED AGENTS   | NON-PREFERRED AGENTS  | PA CRITERIA   |
|--|--|---|---|
| <b>ACNE AGENTS, TOPICAL</b><br><br><i>Effective 4/2/07</i> | <b>ANTIBIOTICS</b>   |   | A trial of 30 days of one of the preferred agents in each category will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.)<br>PA required after 17 years of age for tretinoin products. |
|  | AKNE-MYCIN (erythromycin)<br>clindamycin<br>erythromycin                                   | CLINDAGEL (clindamycin)<br><b>CLINDAREACH (clindamycin)<sup>NR</sup></b><br>EVOCLIN (clindamycin) |   |
|  | <b>RETINOIDS</b>   |   |   |
|  | RETIN-A MICRO (tretinoin) <sup>CL</sup><br>TAZORAC (tazarotene)<br>tretinoin <sup>CL</sup> | DIFFERIN (adapalene)  |   |
| <b>ALZHEIMER'S AGENTS</b><br><br><i>Effective 10/2/06</i>  | <b>CHOLINESTERASE INHIBITORS</b>   |   | A trial of a preferred agent will be required before a non-preferred agent in this class will be authorized.<br>Current prescriptions for Razadyne and Razadyne ER will be grandfathered..  |
|  | ARICEPT (donepezil)<br>EXELON (rivastigmine)   | COGNEX (tacrine)<br>RAZADYNE (galantamine)<br>RAZADYNE ER (galantamine)                           |   |
|  | <b>NMDA RECEPTOR ANTAGONIST</b>  |   |   |
| NAMENDA (memantine)  |  |   |   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA   |
|---|---|--|--|
| <p><b>ANALGESICS, NARCOTIC -<br/>SHORT ACTING</b><br/>(Non-parenteral)</p> <p><i>Effective 4/2/07</i></p> | <p>APAP/codeine<br/>ASA/codeine<br/>codeine<br/>dihydrocodeine/ APAP/caffeine<br/>hydrocodone/APAP<br/>hydrocodone/ibuprofen<br/>hydromorphone<br/>levorphanol<br/>morphine<br/>oxycodone<br/>oxycodone/APAP<br/>oxycodone/ASA<br/>pentazocine/APAP<br/>pentazocine/naloxone<br/>propoxyphene/APAP<br/>tramadol<br/>tramadol/APAP</p> | <p>ACTIQ (fentanyl)<br/>butalbital/APAP/caffeine/codeine<br/>butalbital/ASA/caffeine/codeine<br/>COMBUNOX (oxycodone/ibuprofen)<br/>DARVOCET (propoxyphene/APAP)<br/>DARVON (propoxyphene)<br/>DEMEROL (meperidine)<br/>DILAUDID (hydromorphone)<br/>fentanyl<br/><b>FENTORA (fentanyl)<sup>NR</sup></b><br/>FIORICET W/ CODEINE<br/>(butalbital/APAP/caffeine/codeine<br/>)<br/>FIORINAL W/ CODEINE<br/>(butalbital/ASA/caffeine/codeine)<br/>LORCET, LORTAB<br/>(hydrocodone/APAP)<br/><b>LYNOX (oxycodone/APAP)<sup>NR</sup></b><br/>meperidine<br/>OPANA (oxymorphone)<br/>OXYFAST, OXYIR (oxycodone)<br/>PANLOR<br/>(dihydrocodeine/ APAP/caffeine)<br/>PERCOCET (oxycodone/APAP)<br/>PERCODAN (oxycodone/ASA)<br/>propoxyphene<br/>TALACEN (pentazocine/APAP)<br/>TALWIN NX (pentazocine/naloxone)<br/>TYLENOL W/CODEINE<br/>(APAP/codeine)<br/>ULTRACET (tramadol/APAP)<br/>ULTRAM (tramadol)<br/>VICODIN (hydrocodone/APAP)<br/>VICOPROFEN<br/>(hydrocodone/ibuprofen)</p> | <p>Three of the preferred agents must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy.</p> <p>Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization and review by the Medical Director.</p> |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA   |
|---|--|--|--|
| <b>ANALGESICS, NARCOTIC -<br/>LONG ACTING</b><br>(Non-parenteral)                 | DURAGESIC (fentanyl)<br>KADIAN (morphine)<br>methadone<br>morphine ER  | AVINZA (morphine)<br>fentanyl<br>MS CONTIN (morphine)<br>OPANA ER (oxymorphone)<br>ORAMORPH SR (morphine)<br>oxycodone ER<br>OXYCONTIN (oxycodone)<br>ULTRAM ER (tramadol) | Three preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br><b>Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.</b> |
| <b>ANDROGENIC AGENTS</b><br><br><i>Effective 10/2/06</i>                          | ANDRODERM (testosterone)<br>ANDROGEL (testosterone)  | TESTIM (testosterone)  | The non-preferred agents will be approved only if one of the exceptions on the PA form is present.   |
| <b>ANGIOTENSIN II RECEPTOR<br/>BLOCKERS (ARBs)</b><br><br><i>Effective 4/2/07</i> | <b>ANGIOTENSIN RECEPTOR BLOCKERS</b>   |  | Each of the preferred agents in the corresponding group must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.  |
|   | AVAPRO (irbesartan)<br>BENICAR (olmesartan)<br>COZAAR (losartan)<br>DIOVAN (valsartan)<br>MICARDIS (telmisartan)                                       | ATACAND (candesartan)<br>TEVETEN (eprosartan)  |  |
|   | <b>ARB COMBINATIONS</b>  |  |  |
|   | AVALIDE (irbesartan/HCTZ)<br>BENICAR-HCT (olmesartan/HCTZ)<br>DIOVAN-HCT (valsartan/HCTZ)<br>HYZAAR (losartan/HCTZ)<br>MICARDIS-HCT (telmisartan/HCTZ) | ATACAND-HCT (candesartan/HCTZ)<br>EXFORGE (valsartan/amlodipine) <sup>NR</sup><br>TEVETEN-HCT (eprosartan/HCTZ)  |  |
| <b>ANTICOAGULANTS,<br/>INJECTABLE<sup>CL</sup></b><br><br><i>Effective 4/2/07</i> | ARIXTRA (fondaparinux)<br>FRAGMIN (dalteparin)<br>LOVENOX (enoxaparin)   | INNOHEP (tinzaparin)   | A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS                                | PREFERRED AGENTS   | NON-PREFERRED AGENTS   | PA CRITERIA   |
|---|--|--|---|
| <b>ANTICONVULSANTS</b><br><br><i>Effective 4/2/07</i> | <b>BARBITURATES</b>  |  | Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Patients stabilized on non-preferred agents will receive authorization to continue these drugs. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present. |
|   | mephobarbital<br>phenobarbital<br>primidone  | MEBARAL (mephobarbital)<br>MYSOLINE (primidone)  |   |
|   | <b>HYDANTOINS</b>  |  |   |
|   | PEGANONE (ethotoin)<br>phenytoin   | DILANTIN (phenytoin)<br>EPITOL (phenytoin)<br>PHENYTEK (phenytoin)   |   |
|   | <b>SUCCINIMIDES</b>  |  |   |
|   | CELONTIN (methsuximide)<br>ethosuximide  | ZARONTIN (ethosuximide)  |   |
|   | <b>BENZODIAZEPINES</b>   |  |   |
|   | clonazepam<br>DIASTAT (diazepam rectal)<br>diazepam  | KLONOPIN (clonazepam)  |   |
|   | <b>ADJUVANTS</b>   |  |   |
|   | carbamazepine<br>CARBATROL (carbamazepine)<br>DEPAKOTE (divalproex)<br>DEPAKOTE ER (divalproex)<br>DEPAKOTE SPRINKLE (divalproex)<br>dilvalproex<br>EQUETRO (carbamazepine)<br>FELBATOL (felbamate)<br>gabapentin<br>GABITRIL (tiagabine)<br>KEPPRA (levetiracetam)<br>LAMICTAL (lamotrigine)<br>LYRICA (pregabalin)<br>TOPAMAX (topiramate)<br>TRILEPTAL (oxcarbazepine)<br>valproic acid<br>zonisamide | DEPAKENE (valproic acid)<br>NEURONTIN (gabapentin)<br>TEGRETOL (carbamazepine)<br>TEGRETOL XR (carbamazepine)<br>ZONEGRAN (zonisamide) |   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA  |
|---|--|--|---|
| <b>ANTIDEPRESSANTS, OTHER</b><br>(second generation, non-SSRI)<br><br><i>Effective 4/2/07</i> | bupropion SR<br>CYMBALTA (duloxetine)<br>EFFEXOR XR (venlafaxine)<br>mirtazapine<br>trazodone  | bupropion IR<br>bupropion XL<br>DESYREL (trazodone)<br>EFFEXOR (venlafaxine)<br>EMSAM (selegiline)<br>nefazodone<br>REMERON (mirtazapine)<br>venlafaxine<br>WELLBUTRIN (bupropion)<br>WELLBUTRIN SR (bupropion)<br>WELLBUTRIN XL (bupropion)                                     | A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present.<br><br>Patients on a non-preferred agent will be authorized to continue on that agent.  |
| <b>ANTIDEPRESSANTS, SSRIs</b><br><br><i>Effective 7/9/07</i>                                  | citalopram<br>fluoxetine<br>fluvoxamine<br>LEXAPRO (escitalopram)<br>paroxetine<br>PAXIL CR (paroxetine)<br>PEXEVA (paroxetine)<br><b>sertraline</b> | CELEXA (citalopram)<br>PAXIL (paroxetine)<br>PROZAC (fluoxetine)<br>RAPIFLUX (fluoxetine)<br>SARAFEM (fluoxetine)<br><b>ZOLOFT (sertraline)</b>  | None of the non-preferred dosage forms will be authorized unless there is documentation showing that the preferred dosage forms of the corresponding agents are inappropriate for the patient.  |
| <b>ANTIEMETICS, ORAL</b><br><br><i>Effective 10/2/06</i>                                      | <b>5HT3 RECEPTOR BLOCKERS</b>  |  | A trial of Zofran is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br>Quantity limits for Zofran - 14 tablets per 21 days; in cases of hyperemesis during pregnancy, increased quantities may be authorized.<br><br>Quantity limits for Emend - 12 tablets per 28 days |
|   | ZOFRAN (ondansetron)<br>ZOFRAN ODT (ondansetron)   | ANZEMET (dolasetron)<br>KYTRIL (granisetron)<br>ondansetron  |   |
|   | <b>SUBSTANCE P ANTAGONISTS</b>   |  |   |
|   | EMEND (aprepitant)   |  |   |
| <b>ANTIFUNGALS, ORAL</b><br><br><i>Effective 10/2/06</i>                                      | clotrimazole<br>fluconazole<br>ketoconazole <sup>CL</sup><br>LAMISIL (terbinafine) <sup>CL</sup><br>MYCOSTATIN Pastilles (nystatin)<br>nystatin      | ANCOBON (flucytosine)<br>DIFLUCAN (fluconazole)<br>GRIFULVIN V (griseofulvin)<br>griseofulvin<br>GRIS-PEG (griseofulvin)<br>itraconazole<br>MYCELEX (clotrimazole)<br>MYCOSTATIN Tablets (nystatin)<br>NIZORAL (ketoconazole)<br>SPORANOX (itraconazole)<br>VFEND (voriconazole) | Non-preferred agents will be approved only if one of the exceptions on the PA form is present.<br><br>PA is required when limits are exceeded.<br><br>PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

Version 2007.5

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA  |
|---|---|--|---|
| <b>ANTIFUNGALS, TOPICAL</b><br><br><i>Effective 10/2/06</i>                   | <b>ANTIFUNGALS</b>  |  | Three of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.         |
|   | econazole<br>EXELDERM (sulconazole)<br>ketoconazole<br>NAFTIN (naftifine)<br>nystatin                               | ciclopirox<br>ERTACZO (sertaconazole)<br>LOPROX (ciclopirox)<br>MENTAX (butenafine)<br>MYCOSTATIN (nystatin)<br>NIZORAL (ketoconazole)<br>OXISTAT (oxiconazole)<br>PENLAC (ciclopirox)<br>SPECTAZOLE (econazole)<br>VUSION<br>(miconazole/petrolatum/zinc oxide)<br>XOLEGEL (ketoconazole) <sup>NR</sup> |   |
|   | <b>ANTIFUNGAL/STEROID COMBINATIONS</b>  |  |   |
|   | clotrimazole/betamethasone<br>nystatin/triamcinolone  | LOTRISONE<br>(clotrimazole/betamethasone)<br>MYCOLOG (nystatin/triamcinolone)  |   |
| <b>ANTI-HISTAMINES, MINIMALLY<br/>SEDATING</b><br><br><i>Effective 4/2/07</i> | <b>ANTI-HISTAMINES</b>  |  | A preferred agent, in the age appropriate dosage form, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.                      |
|   | ALAVERT (loratadine)<br>CLARINEX Syrup (desloratadine)<br>loratadine<br>TAVIST-ND (loratadine)                      | ALLEGRA (fexofenadine)<br>CLARINEX Tablets (desloratadine)<br>CLARITIN (loratadine)<br>fexofenadine<br>ZYRTEC (cetirizine)   |   |
|   | <b>ANTI-HISTAMINE/DECONGESTANT COMBINATIONS</b>   |  |   |
|   | ALAVERT-D (loratadine/pseudoephedrine)<br>loratadine/pseudoephedrine<br>SEMPREX-D<br>(acrivastine/ pseudoephedrine) | ALLEGRA-D<br>(fexofenadine/pseudoephedrine)<br>CLARINEX-D<br>(desloratadine/pseudoephedrine)<br>CLARITIN-D<br>(loratadine/pseudoephedrine)<br>ZYRTEC-D<br>(cetirizine/pseudoephedrine)   |   |
| <b>ANTIMIGRAINE AGENTS,<br/>TRIPTRANS</b><br><br><i>Effective 4/2/07</i>      | AMERGE (naratriptan)<br>IMITREX (sumatriptan)<br>MAXALT (rizatriptan)<br>RELPAX (eletriptan)                        | AXERT (almotriptan)<br>FROVA (frovatriptan)<br>ZOMIG (zolmitriptan)  | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.<br><br>Quantity limits apply for this drug class. |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

Version 2007.5

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA   |
|---|---|---|--|
| <b>ANTIPARKINSON'S AGENTS</b><br>(Oral)<br><br><i>Effective 10/2/06</i>         | <b>ANTICHOLINERGICS</b>   |   | Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents before a non-preferred agent will be authorized.  |
|   | benztropine<br>KEMADRIN (procyclidine)<br>trihexyphenidyl   | COGENTIN (benztropine)  |  |
|   | <b>COMT INHIBITORS</b>  |   |  |
|   | COMTAN (entacapone)   | TASMAR (tolcapone)  |  |
|   | <b>DOPAMINE AGONISTS</b>  |   |  |
|   | MIRAPEX (pramipexole)<br>REQUIP (ropinirole)  |   |  |
| <b>OTHER ANTIPARKINSON'S AGENTS</b>   |   |   |  |
| carbidopa/levodopa<br>selegiline<br>STALEVO (levodopa/<br>carbidopa/entacapone) | AZILECT (rasagiline) <sup>NR</sup><br>ELDEPRYL (selegiline)<br>PARCOPA (levodopa/carbidopa)<br>SINEMET (levodopa/carbidopa)<br>ZELAPAR (selegiline) <sup>NR</sup> |   |  |
| <b>ANTIPSYCHOTICS, ATYPICAL</b><br>(Oral)<br><br><i>Effective 10/2/06</i>       | <b>ORAL</b>   |   | Upon discharge, hospitalized patients stabilized on non-preferred agents will receive authorization to continue these drugs.<br><br>New patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present. |
|   | clozapine<br>FAZACLO (clozapine)<br>GEODON (ziprasidone)<br>RISPERDAL (risperidone)<br>SEROQUEL (quetiapine)  | ABILIFY (aripiprazole)<br>CLOZARIL (clozapine)<br>INVEGA (paliperidone) <sup>NR</sup><br>ZYPREXA (olanzapine)   |  |
|   | <b>ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS</b>   |   |  |
|   |   | SYMBYAX (olanzapine/fluoxetine)   |  |
| <b>ANTIVIRALS</b><br>(Oral)<br><br><i>Effective 10/2/06</i>                     | acyclovir<br>amantadine<br>ganciclovir<br>VALCYTE (valganciclovir)<br>VALTREX (valacyclovir)  | CYTOVENE (ganciclovir)<br>FAMVIR (famciclovir)<br>FLUMADINE (rimantadine)<br>rimantadine<br>RELENZA (zanamivir)<br>SYMMETREL (amantadine)<br>TAMIFLU (oseltamivir)<br>ZOVIRAX (acyclovir) | All of the appropriate preferred agents with the applicable indication must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.  |
| <b>ATOPIC DERMATITIS</b><br><br><i>Effective 10/2/06</i>                        | ELIDEL (pimecrolimus)<br>PROTOPIC (tacrolimus)  |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS  | PREFERRED AGENTS  | NON-PREFERRED AGENTS  | PA CRITERIA  |
|---|---|---|--|
| <b>BETA BLOCKERS</b><br>(Oral)<br><br><i>Effective 4/2/07</i>                         | <b>BETA BLOCKERS</b>  |   | If one of the exceptions on the PA form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved. |
|   | acebutolol<br>atenolol<br>betaxolol<br>bisoprolol<br>INDERAL LA (propranolol)<br>metoprolol<br>nadolol<br>pindolol<br>propranolol<br>sotalol<br>timolol<br>TOPROL XL (metoprolol) | BETAPACE (sotalol)<br>BLOCADREN (timolol)<br>CARTROL (carteolol)<br>CORGARD (nadolol)<br>INNOPRAN XL (propranolol)<br>KERLONE (betaxolol)<br>LEVATOL (penbutolol)<br>LOPRESSOR (metoprolol)<br>SECTRAL (acebutolol)<br>TENORMIN (atenolol)<br>ZEBETA (bisoprolol) |  |
|   | <b>BETA- AND ALPHA- BLOCKERS</b>  |   |  |
| <b>BLADDER RELAXANT PREPARATIONS</b><br><br><i>Effective 4/2/07</i>                   | DITROPAN XL (oxybutynin)<br>ENABLEX (darifenacin)<br>oxybutynin<br>oxybutynin ER<br>OXYTROL (oxybutynin)<br>SANCTURA (trospium)<br>VESICARE (solifenacin)                         | DETROL (tolterodine)<br>DETROL LA (tolterodine)<br>DITROPAN (oxybutynin)  | All of the preferred agents in the class must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.   |
| <b>BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b><br><br><i>Effective 10/2/06</i> | <b>BISPHOSPHONATES</b>  |   | One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.                               |
|   | FOSAMAX (alendronate)<br>FOSAMAX PLUS D (alendronate/vitamin D)   | ACTONEL (risedronate)<br>ACTONEL WITH CALCIUM (risedronate/calcium)<br>BONIVA (ibandronate)<br>DIDRONEL (etidronate)  |  |
| <b>OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>                           |   |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA   |
|---|---|--|--|
|   | EVISTA (raloxifene)<br>MIACALCIN (calcitonin)   | FORTEO (teriparatide)<br>FORTICAL (calcitonin)   |  |
| <b>BPH AGENTS</b><br><br><i>Effective 4/2/07</i>                            | <b>ALPHA BLOCKERS</b>   |  | One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.  |
|   | doxazosin<br>FLOMAX (tamsulosin)<br>terazosin<br>UROXATRAL (alfuzosin)                          | CARDURA (doxazosin)<br>CARDURA XL (doxazosin)<br>HYTRIN (terazosin)  |  |
|   | <b>5-ALPHA-REDUCTASE (5AR) INHIBITORS</b>   |  |  |
|   | AVODART (dutasteride)   | finasteride<br>PROSCAR (finasteride)   |  |
| <b>BRONCHODILATORS,<br/>ANTICHOLINERGIC</b><br><br><i>Effective 10/2/06</i> | <b>ANTICHOLINERGIC</b>  |  | The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br>For severely compromised patients, DuoNeb will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.   |
|   | ATROVENT CFC (ipratropium)<br>ATROVENT HFA (ipratropium)<br>ipratropium<br>SPIRIVA (tiotropium) | ATROVENT Inhalation Solution<br>(ipratropium)  |  |
|   | <b>ANTICHOLINERGIC-BETA AGONIST COMBINATIONS</b>  |  |  |
|   | COMBIVENT (albuterol/ipratropium)   | DUONEB (albuterol/ipratropium)   |  |
| <b>BRONCHODILATORS, BETA<br/>AGONIST</b><br><br><i>Effective 10/2/06</i>    | <b>INHALERS, SHORT-ACTING</b>   |  | All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.<br><br>Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for a concurrent diagnosis of heart disease. |
|   | albuterol CFC<br>MAXAIR (pirbuterol)<br>XOPENEX HFA (levalbuterol)                              | ALUPENT (metaproterenol)<br>PROAIR HFA (albuterol)<br>PROVENTIL (albuterol)<br>PROVENTIL HFA (albuterol)<br>VENTOLIN HFA (albuterol) |  |
|   | <b>INHALERS, LONG-ACTING</b>  |  |  |
|   | FORADIL (formoterol)  | SEREVENT (salmeterol)  |  |
|   | <b>INHALATION SOLUTION</b>  |  |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS   | NON-PREFERRED AGENTS  | PA CRITERIA  |
|--|--|---|--|
|  | albuterol  | ACCUNEB (albuterol)**<br>BROVANA (arformoterol) <sup>NR</sup><br>metaproterenol<br>PROVENTIL (albuterol)<br>XOPENEX (levalbuterol)  | **No PA is required for ACCUNEB for children up to 5 years of age.   |
|  | <b>ORAL</b>  |   |  |
| <b>CALCIUM CHANNEL BLOCKERS (Oral)</b><br><br><i>Effective 4/2/07</i>  |  | <b>SHORT-ACTING</b>   | One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br>Nimodipine will be approved with the appropriate diagnosis. |
|  | diltiazem<br>verapamil   | ADALAT (nifedipine)<br>CALAN (verapamil)<br>CARDENE (nicardipine)<br>CARDIZEM (diltiazem)<br>DYNACIRC (isradipine)<br>isradipine<br>nicardipine<br>nifedipine<br>NIMOTOP (nimodipine)<br>PROCARDIA (nifedipine) |  |
|  |  | <b>LONG-ACTING</b>  |  |
| CARDIZEM LA (diltiazem)<br>diltiazem<br>DYNACIRC CR (isradipine)<br>felodipine<br>nifedipine<br>SULAR (nisoldipine)<br>verapamil<br>VERELAN PM (verapamil) | ADALAT CC (nifedipine)<br>amlodipine<br>CALAN SR (verapamil)<br>CARDENE SR (nicardipine)<br>CARDIZEM CD (diltiazem)<br>CARDIZEM SR (diltiazem)<br>COVERA-HS (verapamil)<br>DILACOR XR (diltiazem)<br>ISOPTIN SR (verapamil)<br>NORVASC (amlodipine)<br>PLENDIL (felodipine)<br>PROCARDIA XL (nifedipine) |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA   |
|---|---|--|--|
|   |   | TIAZAC (diltiazem)<br>VERELAN (verapamil)  |  |
| <b>CEPHALOSPORINS AND<br/>RELATED ANTIBIOTICS</b><br>(Oral)<br><br><i>Effective 10/2/06</i> | <b>BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS</b>  |  | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
|   | amoxicillin/clavulanate<br>AUGMENTIN XR (amoxicillin/clavulanate)   | AUGMENTIN (amoxicillin/clavulanate)<br>AUGMENTIN ES-600<br>(amoxicillin/clavulanate)   |  |
|   | <b>CEPHALOSPORINS</b>   |  |  |
|   | CEDAX (ceftibuten)<br>cefaclor<br>cefadroxil<br>cefprozil<br>cefuroxime<br>cephalexin<br>OMNICEF (cefdinir)<br>SPECTRACEF (cefditoren)<br>SUPRAX (cefixime) | CECLOR (cefaclor)<br>cefdinir<br>cefpodoxime<br>CEFTIN (cefuroxime)<br>CEFZIL (cefprozil)<br>DURICEF (cefadroxil)<br>KEFLEX (cephalexin)<br>PANIXINE (cephalexin)<br>RANICLOR (cefaclor)<br>VANTIN (cefpodoxime) |  |
| <b>CYTOKINE &amp; CAM<br/>ANTAGONISTS<sup>CL</sup></b><br><br><i>Effective 10/2/06</i>      | ENBREL (etanercept)<br>HUMIRA (adalimumab)<br>KINERET (anakinra)<br>RAPTIVA (efalizumab)  |  |  |
| <b>ERYTHROPOIESIS<br/>STIMULATING PROTEINS<sup>CL</sup></b><br><br><i>Effective 4/2/07</i>  | ARANESP (darbepoetin)<br>PROCRT (rHuEPO)  | EPOGEN (rHuEPO)  | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS   | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA  |
|---|--|---|---|
| <b>FLUROQUINOLONES, ORAL</b><br><br><i>Effective 10/2/06</i>      | AVELOX (moxifloxacin)<br>CIPRO (ciprofloxacin) Suspension<br>ciprofloxacin<br>FACTIVE (gemifloxacin)                           | CIPRO (ciprofloxacin) Tablets<br>CIPRO XR (ciprofloxacin)<br>FLOXIN (ofloxacin)<br>LEVAQUIN (levofloxacin)<br>ofloxacin<br>PROQUIN XR (ciprofloxacin) | One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.   |
| <b>GLUCOCORTICIDS, INHALED</b><br><br><i>Effective 10/2/06</i>    | <b>GLUCOCORTICIDS</b>  |   | All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.<br><br>Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI.<br><br>Flovent HFA will not require a PA for children through age 6. |
|   | AEROBID (flunisolide)<br>AEROBID-M (flunisolide)<br>ASMANEX (mometasone)<br>AZMACORT (triamcinolone)<br>QVAR (beclomethasone)  | FLOVENT HFA (fluticasone)<br>PULMICORT (budesonide)   |   |
|   | <b>GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS</b>  |   |   |
|   | ADVAIR (fluticasone/salmeterol)<br>ADVAIR HFA<br>(fluticasone/salmeterol)  | <b>SYMBICORT</b><br><b>(budesonide/formoterol)<sup>NR</sup></b>   |   |
| <b>GROWTH HORMONE<sup>CL</sup></b><br><br><i>Effective 4/2/07</i> | GENOTROPIN (somatropin)<br>NUTROPIN AQ (somatropin)<br>SAIZEN (somatropin)<br>SEROSTIM (somatropin)<br>TEV-TROPIN (somatropin) | HUMATROPE (somatropin)<br>NORDITROPIN (somatropin)<br>NUTROPIN (somatropin)<br><b>OMNITROPE (somatropin)<sup>NR</sup></b><br>ZORBTIVE (somatropin)    | The preferred agents, with the exception of Saizen, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.<br><br>Patients already on a non-preferred agent will receive authorization to continue therapy on that agent.  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS                                    | NON-PREFERRED AGENTS   | PA CRITERIA  |
|--|---|--|--|
| <p><b>HEPATITIS C TREATMENTS<sup>CL</sup></b><br/><br/><i>Effective 4/2/07</i></p>   | <p>PEGASYS (pegylated interferon)<br/>ribavirin</p> | <p>COPEGUS (ribavirin)<br/>INFERGEN (consensus interferon)<br/>PEG-INTRON (pegylated interferon)<br/>REBETOL (ribavirin)</p> | <p>Patients already on a non-preferred interferon will receive authorization to continue therapy on that agent.</p> <p>Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.</p>  |
| <p><b>HYPOGLYCEMICS, INSULINS AND RELATED AGENTS</b><br/><br/><i>Effective 10/2/06</i></p>   | <b>INSULIN</b>                                      |  | <p>To receive authorization for Exubera, patients must meet the following criteria:</p> <ol style="list-style-type: none"> <li>1. be 18 years or older;</li> <li>2. have no history of smoking in the past six months;</li> <li>3. have no history of chronic lung disease in the past two years or presence of acute lower respiratory lung infection;</li> <li>4. have a base line spirometry to measure FEV1. For renewal, spirometry to measure FEV1 six months after treatment initiation and then annually from second FEV1 measure;</li> <li>5. have a diagnosis of Type 1 diabetes (stated or inferred) with concomitant use of a longer acting insulin;</li> </ol> <p align="center">OR</p> |
| <p>HUMALOG (insulin lispro)<br/>HUMALOG MIX (insulin lispro/lispro protamine)<br/>HUMULIN (insulin)<br/>LANTUS (insulin glargine)<br/>LEVEMIR (insulin detemir)<br/>NOVOLIN (insulin)<br/>NOVOLOG (insulin aspart)<br/>NOVOLOG MIX (insulin aspart/aspart protamine)</p> |   | <p>APIDRA (insulin glulisine)<br/>EXUBERA (insulin)<sup>NR</sup></p>   |  |
| <b>RELATED AGENTS</b>  |   |  |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS  | PREFERRED AGENTS  | NON-PREFERRED AGENTS                  | PA CRITERIA  |
|---|---|---------------------------------------|--|
|   | BYETTA (exenatide)<br>SYMLIN (amylin)   |                                       | <p>have a diagnosis of Type 2 diabetes (stated or inferred) and maximization of dosage of at least one available oral agent (sulfonylurea, metformin or thiazolidinediones), unless contraindicated;</p> <p>6. have a diagnosis of lipodystrophy or needle phobia that prevents self-injection or injection by a caregiver.</p> <p>To receive authorization for Apidra, patients must meet the following criteria:</p> <ol style="list-style-type: none"> <li>be 18 years or older;</li> <li>be currently on a regimen including a longer-acting or basal insulin.</li> <li>have had a trial of a similar preferred agent, Novolog or Humulin, with documentation that the desired results were not achieved.</li> </ol> |
| <b>HYPOGLYCEMICS, MEGLITINIDES</b><br><br><i>Effective 4/2/07</i> | STARLIX (nateglinide)   | PRANDIN (repaglinide)                 | The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.   |
| <b>HYPOGLYCEMICS, TZDS</b><br><br><i>Effective 4/2/07</i>         | <b>THIAZOLIDINEDIONES</b>   |                                       |  |
|   | ACTOS (pioglitazone)<br>AVANDIA (rosiglitazone)   |                                       |  |
|   | <b>TZD COMBINATIONS</b>   |                                       |  |
|   | ACTOPLUS MET (pioglitazone/metformin)<br>AVANDAMET (rosiglitazone/metformin)<br>AVANDARYL (rosiglitazone/glimepiride)<br>DUETACT (pioglitazone/glimepiride) |                                       |  |
| <b>INTRANASAL RHINITIS AGENTS</b><br><br><i>Effective 10/2/06</i> | <b>ANTICHOLINERGICS</b>   |                                       | All of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.  |
|   |   | ATROVENT (ipratropium)<br>ipratropium |  |
|   | <b>ANTIHISTAMINES</b>   |                                       |  |
|   | ASTELEN (azelastine)  |                                       |  |
|   | <b>CORTICOSTEROIDS</b>  |                                       |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS   | NON-PREFERRED AGENTS  | PA CRITERIA   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
|--|--|---|---|--|------------------------------|---|--|--|--|-------------------|--------------------|--|--|------------------------------------|--------------------------------|--|--|--|---------------|--|----------------------------|--|---|
|  | FLONASE (fluticasone propionate)<br>NASACORT AQ (triamcinolone)<br>NASONEX (mometasone)  | BECONASE AQ (beclomethasone)<br>flunisolide<br>fluticasone propionate<br>NASALIDE (flunisolide)<br>NASAREL (flunisolide)<br>RHINOCORT AQUA (budesonide)<br>VERAMYST (fluticasone furoate) <sup>NR</sup> |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>LEUKOTRIENE MODIFIERS</b><br><br><i>Effective 10/2/06</i>           | ACCOLATE (zafirlukast)<br>SINGULAIR (montelukast)  | ZYFLO (zileuton)  |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>LIPOTROPICS, OTHER (non-statins)</b><br><br><i>Effective 4/2/07</i> | <table border="1"> <thead> <tr> <th colspan="2" data-bbox="401 623 1333 657"><b>BILE ACID SEQUESTRANTS</b></th> </tr> </thead> <tbody> <tr> <td data-bbox="401 657 942 743">cholestyramine<br/>colestipol</td> <td data-bbox="942 657 1333 743">COLESTID (colestipol)<br/>QUESTRAN (cholestyramine)<br/>WELCHOL (colesevalam)</td> </tr> <tr> <th colspan="2" data-bbox="401 743 1333 777"><b>CHOLESTEROL ABSORPTION INHIBITORS</b></th> </tr> <tr> <td data-bbox="401 777 942 808"></td> <td data-bbox="942 777 1333 808">ZETIA (ezetimibe)</td> </tr> <tr> <th colspan="2" data-bbox="401 808 1333 842"><b>FATTY ACIDS</b></th> </tr> <tr> <td data-bbox="401 842 942 894"></td> <td data-bbox="942 842 1333 894">OMACOR (omega-3-acid ethyl esters)</td> </tr> <tr> <th colspan="2" data-bbox="401 894 1333 928"><b>FIBRIC ACID DERIVATIVES</b></th> </tr> <tr> <td data-bbox="401 928 942 1045">fenofibrate<br/>gemfibrozil<br/>TRICOR (fenofibrate)</td> <td data-bbox="942 928 1333 1045">ANTARA (fenofibrate)<br/>LOFIBRA (fenofibrate)<br/>LOPID (gemfibrozil)<br/>TRIGLIDE (fenofibrate)</td> </tr> <tr> <th colspan="2" data-bbox="401 1045 1333 1079"><b>NIACIN</b></th> </tr> <tr> <td data-bbox="401 1079 942 1226">niacin<br/>NIASPAN (niacin)</td> <td data-bbox="942 1079 1333 1226">NIACELS (niacin)<br/>NIADELAY (niacin)<br/>SLO-NIACIN (niacin)</td> </tr> </tbody> </table> |   | <b>BILE ACID SEQUESTRANTS</b>   |  | cholestyramine<br>colestipol | COLESTID (colestipol)<br>QUESTRAN (cholestyramine)<br>WELCHOL (colesevalam) | <b>CHOLESTEROL ABSORPTION INHIBITORS</b> |  |  | ZETIA (ezetimibe) | <b>FATTY ACIDS</b> |  |  | OMACOR (omega-3-acid ethyl esters) | <b>FIBRIC ACID DERIVATIVES</b> |  | fenofibrate<br>gemfibrozil<br>TRICOR (fenofibrate) | ANTARA (fenofibrate)<br>LOFIBRA (fenofibrate)<br>LOPID (gemfibrozil)<br>TRIGLIDE (fenofibrate) | <b>NIACIN</b> |  | niacin<br>NIASPAN (niacin) | NIACELS (niacin)<br>NIADELAY (niacin)<br>SLO-NIACIN (niacin) | <p>The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents.</p> <p>Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy.</p> <p>If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If patients are on other statins and require the addition of Zetia, patients will not be required to switch the statin that they have been using.</p> |
| <b>BILE ACID SEQUESTRANTS</b>  |  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| cholestyramine<br>colestipol   | COLESTID (colestipol)<br>QUESTRAN (cholestyramine)<br>WELCHOL (colesevalam)  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>CHOLESTEROL ABSORPTION INHIBITORS</b>                               |  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
|  | ZETIA (ezetimibe)  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>FATTY ACIDS</b>   |  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
|  | OMACOR (omega-3-acid ethyl esters)   |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>FIBRIC ACID DERIVATIVES</b>   |  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| fenofibrate<br>gemfibrozil<br>TRICOR (fenofibrate)                     | ANTARA (fenofibrate)<br>LOFIBRA (fenofibrate)<br>LOPID (gemfibrozil)<br>TRIGLIDE (fenofibrate)   |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>NIACIN</b>  |  |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| niacin<br>NIASPAN (niacin)   | NIACELS (niacin)<br>NIADELAY (niacin)<br>SLO-NIACIN (niacin)   |   |   |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |
| <b>LIPOTROPICS, STATINS</b>  | <b>STATINS</b>   |   | One of the preferred statins must be tried before a non-preferred agent |  |                              |   |  |  |  |                   |                    |  |  |                                    |                                |  |  |  |               |  |                            |  |   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS  | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA   |
|--|---|---|--|
| <i>Effective 4/2/07</i>  | ALTOPREV (lovastatin)<br>CRESTOR (rosuvastatin)<br>LESCOL (fluvastatin)<br>LESCOL XL (fluvastatin)<br>LIPITOR (atorvastatin)<br>lovastatin<br>simvastatin | MEVACOR (lovastatin)<br>PRAVACHOL (pravastatin)<br>pravastatin<br>ZOCOR (simvastatin)   | will be authorized unless one of the exceptions on the PA form is present.   |
|  | <b>STATIN COMBINATIONS</b>  |   |  |
|  | ADVICOR (lovastatin/niacin)<br>VYTORIN (ezetimibe/simvastatin)  | CADUET (atorvastatin/amlodipine)  |  |
| <b>MACROLIDES/KETOLIDES</b><br>(Oral)<br><br><i>Effective 10/2/06</i>        | <b>MACROLIDES</b>   |   | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
|  | azithromycin<br>BIAXIN XL (clarithromycin)<br>erythromycin  | BIAXIN (clarithromycin)<br>clarithromycin<br>E.E.S. (erythromycin ethylsuccinate)<br>E-MYCIN (erythromycin)<br>ERYC (erythromycin)<br>ERYPED (erythromycin ethylsuccinate)<br>ERY-TAB (erythromycin)<br>ERYTHROCIN (erythromycin stearate)<br>PCE (erythromycin)<br>ZITHROMAX (azithromycin)<br>ZMAX (azithromycin) |  |
|  | <b>KETOLIDES</b>  |   | Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days.              |
|  |   | KETEK (telithromycin)   |  |
| <b>MULTIPLE SCLEROSIS AGENTS<sup>CL</sup></b><br><br><i>Effective 4/2/07</i> | AVONEX (interferon beta-1a)<br>BETASERON (interferon beta-1b)<br>COPAXONE (glatiramer)<br>REBIF (interferon beta-1a)                                      |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS                     | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA   |
|---|--|--|--|
| <b>NSAIDS</b><br><br><i>Effective 10/2/06</i> | <b>NONSELECTIVE</b>  |  | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
|   | diclofenac<br>etodolac<br>fenoprofen<br>flurbiprofen<br>ibuprofen (Rx and OTC)<br>indomethacin<br>ketoprofen<br>ketorolac<br>naproxen (Rx only)<br>oxaprozin<br>piroxicam<br>PONSTEL (meclofenamate)<br>sulindac<br>tolmetin | ADVIL (ibuprofen)<br>ANAPROX (naproxen)<br>ANSAID (flurbiprofen)<br>CATAFLAM (diclofenac)<br>CLINORIL (sulindac)<br>DAYPRO (oxaprozin)<br>FELDENE (piroxicam)<br>INDOCIN (indomethacin)<br>LODINE (etodolac)<br>meclofenamate<br>mefenamic acid<br>MOTRIN (ibuprofen)<br>nabumetone<br>NALFON (fenoprofen)<br>NAPRELAN (naproxen)<br>NAPROSYN (naproxen)<br>NUPRIN (ibuprofen)<br>ORUDIS (ketoprofen)<br>VOLTAREN (diclofenac) |  |
|   | <b>NSAID/GI PROTECTANT COMBINATIONS</b>  |  |  |
|   |  | ARTHROTEC<br>(diclofenac/misoprostol)<br>PREVACID NAPRAPAC<br>(naproxen/lansoprazole)  |  |
|   | <b>COX-II SELECTIVE<sup>CL</sup></b>   |  | COX-II selective NSAIDs will be approved for patients with a GI Risk Score of $\geq 13$ .  |
|   | CELEBREX (celecoxib)<br>meloxicam<br>MOBIC (meloxicam)   |  |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS   | NON-PREFERRED AGENTS  | PA CRITERIA  |
|--|--|---|--|
| <b>OPHTHALMIC ANTIBIOTICS</b><br><br><i>Effective 10/2/06</i>  | <b>FLUOROQUINOLONES</b>  |   | All of the preferred agents must be tried before non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
|  | VIGAMOX (moxifloxacin)   | ciprofloxacin<br>CILOXAN (ciprofloxacin)<br>OCUFLOX (ofloxacin)<br>ofloxacin<br>QUIXIN (levofloxacin)<br>ZYMAR (gatifloxacin) |  |
|  | <b>OTHER SINGLE AGENTS</b>   |   |  |
|  | bacitracin<br>erythromycin<br>gentamicin<br>sulfacetamide<br>tobramycin  | BLEPH-10 (sulfacetamide)<br>GENOPTIC (gentamicin)<br>TOBREX (tobramycin)  |  |
|  | <b>COMBINATION AGENTS</b>  |   |  |
| neomycin/polymyxin/bacitracin<br>neomycin/polymyxin/gramicidin<br>polymyxin/bacitracin<br>polymyxin/trimethoprim | NEOSPORIN<br>(neomycin/polymyxin/bacitracin)<br>NEOSPORIN<br>(neomycin/polymyxin/gramicidin)<br>POLYSPORIN (polymyxin/bacitracin)<br>POLYTRIM (polymyxin/trimethoprim) |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC<br>DRUG CLASS  | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS  | PA<br>CRITERIA  |
|--|--|--|---|
| <b>OPHTHALMICS FOR ALLERGIC<br/>CONJUNCTIVITIS</b><br><br><i>Effective 10/2/06</i> | ACULAR (ketorolac)<br>ALREX (loteprednol)<br>cromolyn<br>ELESTAT (epinastine)<br>OPTIVAR (azelastine)<br><b>PATADAY (olopatadine)</b><br>PATANOL (olopatadine) | ALOCRIL (nedocromil)<br>ALAMAST (pemirolast)<br><b>ALAWAY (ketotifen)<sup>NR</sup></b><br>ALOMIDE (lodoxamide)<br>CROLOM (cromolyn)<br>EMADINE (emedastine)<br>ketotifen<br>OPTICROM (cromolyn)<br>ZADITOR (ketotifen) | All of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present. |
| <b>OPHTHALMICS, GLAUCOMA<br/>AGENTS</b><br><br><i>Effective 10/2/06</i>            | <b>PARASYMPATHOMIMETICS</b>  |  | Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.  |
|  | CARBOPTIC (carbachol)<br>ISOPTO CARBACHOL (carbachol)<br>PHOSPHOLINE IODIDE (echothiophate iodide)<br>pilocarpine  | ISOPTO CARPINE (pilocarpine)<br>PILOPINE HS (pilocarpine)  |   |
|  | <b>SYMPATHOMIMETICS</b>  |  |   |
|  | ALPHAGAN P (brimonidine)<br>brimonidine<br>dipivefrin  | ALPHAGAN (brimonidine)<br>PROPINE (dipivefrin)   |   |
|  | <b>BETA BLOCKERS</b>   |  |   |
|  | BETIMOL (timolol)<br>BETOPTIC S (betaxolol)<br>betaxolol<br>carteolol<br>levobunolol<br>metipranolol<br>timolol  | BETAGAN (levobunolol)<br>ISTALOL (timolol)<br>OPTIPRANOLOL (metipranolol)<br>TIMOPTIC (timolol)  |   |
|  | <b>CARBONIC ANHYDRASE INHIBITORS</b>   |  |   |
|  | AZOPT (brinzolamide)<br>TRUSOPT (dorzolamide)  |  |   |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| <b>THERAPEUTIC DRUG CLASS</b>  | <b>PREFERRED AGENTS</b>   | <b>NON-PREFERRED AGENTS</b>   | <b>PA CRITERIA</b>   |
|--|---|---|--|
|  | <b>PROSTAGLANDIN ANALOGS</b>  |   |  |
|  | LUMIGAN (bimatoprost)<br>TRAVATAN (travoprost)                          | XALATAN (latanoprost)   |  |
|  | <b>COMBINATION AGENTS</b>   |   |  |
|  | COSOPT (dorzolamide/timolol)  |   |  |
| <b>OTIC FLUOROQUINOLONES</b><br><br><i>Effective 4/2/07</i>            | CIPRODEX (ciprofloxacin/dexamethasone)<br>FLOXIN (ofloxacin)            | CIPRO HC (ciprofloxacin/hydrocortisone)   | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  |
| <b>PHOSPHATE BINDERS</b><br><br><i>Effective 4/2/07</i>                | FOSRENOL (lanthanum)<br>PHOSLO (calcium acetate)<br>RENAGEL (sevelamer) |   |  |
| <b>PLATELET AGGREGATION INHIBITORS</b><br><br><i>Effective 10/2/06</i> | AGGRENOX (dipyridamole/ASA)<br>PLAVIX (clopidogrel)                     | dipyridamole<br>PERSANTINE (dipyridamole)<br>TICLID (ticlopidine)<br>ticlopidine  | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  |
| <b>PROTON PUMP INHIBITORS</b><br>(Oral)<br><br><i>Effective 4/2/07</i> | NEXIUM (esomeprazole)<br>PREVACID Capsules (lansoprazole)               | ACIPHEX (rabeprazole)<br>omeprazole<br>PREVACID Solu-Tabs (lansoprazole)<br>PREVACID Suspension (lansoprazole)<br>PRILOSEC (omeprazole)<br>PROTONIX (pantoprazole)<br>ZEGERID (omeprazole/sodium bicarbonate) | The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.<br>Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age. |
| <b>SEDATIVE HYPNOTICS</b><br><br><i>Effective 4/2/07</i>               | <b>BENZODIAZEPINES</b>  |   |  |
|  | temazepam   | DALMANE (flurazepam)<br>DORAL (quazepam)<br>estazolam<br>flurazepam<br>HALCION (triazolam)<br>PROSOM (estazolam)<br>RESTORIL (temazepam)<br>triazolam   | The preferred agent must be tried for 14 days before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.  |
|  | <b>OTHERS</b>   |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| THERAPEUTIC DRUG CLASS   | PREFERRED AGENTS   | NON-PREFERRED AGENTS  | PA CRITERIA  |
|--|--|---|--|
|  | zolpidem   | AMBIEN (zolpidem)<br>AMBIEN CR (zolpidem)<br>AQUA CHLORAL (chloral hydrate)<br>chloral hydrate<br>LUNESTA (eszopiclone)<br>ROZEREM (ramelteon)<br>SOMNOTE (chloral hydrate)<br>SONATA (zaleplon)                            |  |
| <b>STIMULANTS AND RELATED AGENTS</b><br><br><i>Effective 10/2/06</i> | <b>AMPHETAMINES</b>  |   | Except for Strattera, PA is required for adults >18 years.   |
|  | ADDERALL XR<br>(amphetamine salt combination)<br>amphetamine salt combination<br>dextroamphetamine   | ADDERALL<br>(amphetamine salt combination)<br>DESOXYN (methamphetamine)<br>DEXTROSTAT (dextroamphetamine)   | One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized.   |
|  | <b>NON-AMPHETAMINE</b>   |   |  |
|  | CONCERTA (methylphenidate)<br>FOCALIN (dexmethylphenidate)<br>FOCALIN XR (dexmethylphenidate)<br>METADATE CD (methylphenidate)<br>methylphenidate<br>methylphenidate ER<br>STRATTERA (atomoxetine) | DAYTRANA (methylphenidate) <sup>NR</sup><br><b>dexmethylphenidate</b><br>METADATE ER (methylphenidate)<br>PROVIGIL (modafanil)<br>RITALIN (methylphenidate)<br>RITALIN LA (methylphenidate)<br>RITALIN-SR (methylphenidate) | Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants.<br><br>Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy.<br><br>Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period. |
| <b>ULCERATIVE COLITIS AGENTS</b><br><br><i>Effective 4/2/07</i>      | <b>ORAL</b>  |   |  |
|  | ASACOL (mesalamine)<br>COLAZAL (balsalazide)<br>DIPENTUM (olsalazine)<br>PENTASA (mesalamine)<br>sulfasalazine   | AZULFIDINE (sulfasalazine)<br><b>LIALDA (mesalamine)<sup>NR</sup></b>   | The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.  |
|  | <b>RECTAL</b>  |   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 8/7/07  
Implementation Date: 7/09/07  
Originally Posted: 3/15/07**

**Version 2007.5**

| <b>THERAPEUTIC<br/>DRUG CLASS</b> | <b>PREFERRED<br/>AGENTS</b>       | <b>NON-PREFERRED<br/>AGENTS</b> | <b>PA<br/>CRITERIA</b> |
|-----------------------------------|-----------------------------------|---------------------------------|------------------------|
|                                   | CANASA (mesalamine)<br>mesalamine | ROWASA (mesalamine)             |                        |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> - Requires Clinical PA

<sup>NR</sup> – New drug has not been reviewed by P & T Committee